9 completed, 1 active not recruiting, 1 terminated. 11 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hepatitis C Infection: new trials by email Literature Review of Hepatitis C Infection trials Research Report on Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis - Chronic Hepatitis, Hepatitis C Infection | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2016-06-06 | 2026-09-11 |
| A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals AdCh3NSmut1, MVA-NSmut - Hepatitis C Infection | Phase 1 | Completed | University of Oxford | 20 | 2015-07-21 | 2018-10-11 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir Daclatasvir, Asunaprevir - Hepatitis C Infection | Phase 1 | Completed | Bristol-Myers Squibb | 88 | 2014-12-01 | 2015-02-24 |
| A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv - Hepatitis C Infection, HIV Infection | Phase 1 | Completed | University of Oxford | 33 | 2014-10-01 | 2018-10-11 |
| Study of Drug Combination on Pharmacokinetics in Healthy Volunteers Escitalopram, Sertraline, DCV 3DAA FDC - Hepatitis C Infection | Phase 1 | Completed | Bristol-Myers Squibb | 41 | 2014-06-01 | 2015-02-10 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) Ruzasvir - Hepatitis C Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2014-03-27 | 2018-12-24 |
| A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection SB9200, Placebo - Hepatitis C Infection | Phase 1 | Completed | Syneos Health | 37 | 2013-03-01 | 2019-09-18 |
| Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection ITX 5061 - Hepatitis C Infection | Phase 1 | Terminated | Schiano, Thomas D., MD | 10 | 2012-03-01 | 2018-04-18 |
| Study of a New MVA Vaccine for Hepatitis C Virus MVA-NSmut, AdCh3NSmut, AdCh3NSmut1 - Hepatitis C Infection | Phase 1 | Completed | ReiThera Srl | 55 | 2010-12-01 | 2016-04-26 |
| A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures Nitazoxanide With Pegylated Interferon And Ribavirin - Hepatitis C Infection, HIV Infection | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 8 | 2010-08-01 | 2021-10-05 |
Hepatitis C (11) · Carcinoma, Hepatocellular (2) · HIV Infections (2) · Adenoviridae Infections (1) · Bronchiolitis Obliterans Syndrome (1) · Fibrosis (1) · Hepatitis B (1) · Hepatitis, Chronic (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Persistent Infection (1)
Blood-Borne Infections (11) · Communicable Diseases (11) · Digestive System Diseases (11) · Flaviviridae Infections (11) · Hepatitis (11) · Hepatitis, Viral, Human (11) · Infections (11) · Liver Diseases (11) · RNA Virus Infections (11) · Virus Diseases (11) · Immune System Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Adenocarcinoma (2) · Carcinoma (2)
8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide (1) · Escitalopram (1) · Ribavirin (1) · Sertraline (1) · Sorafenib (1) · asunaprevir (1) · daclatasvir (1) · navitoclax (1) · nitazoxanide (1) · rocakinogene sifuplasmid (1) · ruzasvir (1)
Bristol-Myers Squibb (2) · National Cancer Institute (NCI) (2) · University of Oxford (2) · Merck Sharp & Dohme LLC (1) · National Institutes of Health Clinical Center (CC) (1) · ReiThera Srl (1) · Schiano, Thomas D., MD (1) · Syneos Health (1)
United States (4) · United Kingdom (2) · Australia (1) · Ireland (1) · New Zealand (1) · Puerto Rico (1) · Switzerland (1)
Alexander Thompson, MD, PhD (1) · Brian A Costello (1) · Colm Bergin, Prof (1) · David Gorard, Dr (1) · Donald Mitchell (1) · Eleanor Barnes, Dr. (1) · Ellie Barnes, Prof (1) · Ellie Barnes, Prof. (1) · Ikenna Ogbaa, MD (1) · Jeffrey M Jacobson (1) · Lucy Dorrell, Prof (1) · Lucy Dorrell, Prof. (1) · Matthias Hoffmann, Dr (1) · Paul Klenerman, Prof. (1)
PMID 24041792, PMID 25378645, PMID 30713538, PMID 33317695
2009 (1), N01CN00042 (1), P30CA015083 (1), UM1CA186686 (1)